Chiome Bioscience Inc. (TYO:4583)
Japan · Delayed Price · Currency is JPY 133.00
-5.00 (-3.62%)
Sep 10, 2025, 3:30 PM JST
Chiome Bioscience Income Statement
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
| 768.88 | 780.81 | 682.46 | 630.82 | 712.93 | 480.85 | Upgrade | |
Revenue Growth (YoY) | 30.92% | 14.41% | 8.19% | -11.52% | 48.26% | 7.43% | Upgrade |
Cost of Revenue | 331.92 | 347.96 | 283.87 | 281.96 | 290.47 | 235.58 | Upgrade |
Gross Profit | 436.96 | 432.85 | 398.6 | 348.86 | 422.46 | 245.27 | Upgrade |
Selling, General & Admin | 537.73 | 526.98 | 551.86 | 471.9 | 444.59 | 372.31 | Upgrade |
Research & Development | 885.79 | 936.74 | 1,052 | 1,136 | 1,312 | 1,157 | Upgrade |
Operating Expenses | 1,424 | 1,464 | 1,604 | 1,608 | 1,757 | 1,529 | Upgrade |
Operating Income | -986.55 | -1,031 | -1,205 | -1,259 | -1,334 | -1,284 | Upgrade |
Interest Expense | -3.52 | -2.87 | -2.07 | -1.32 | -1.32 | -0.97 | Upgrade |
Interest & Investment Income | 1.11 | 0.22 | 0.02 | 0.02 | 0.03 | 0.03 | Upgrade |
Currency Exchange Gain (Loss) | 0.62 | 0.92 | 0.51 | -0.57 | 6.63 | 0.85 | Upgrade |
Other Non Operating Income (Expenses) | -6.53 | 13.39 | -10.54 | 16.69 | -0.33 | -7.9 | Upgrade |
EBT Excluding Unusual Items | -994.89 | -1,019 | -1,217 | -1,244 | -1,329 | -1,292 | Upgrade |
Gain (Loss) on Sale of Investments | - | - | - | - | -150 | - | Upgrade |
Other Unusual Items | 0.72 | 1.67 | 2.23 | 5.98 | 12.91 | 1.05 | Upgrade |
Pretax Income | -994.16 | -1,018 | -1,215 | -1,238 | -1,466 | -1,291 | Upgrade |
Income Tax Expense | 2.95 | 3.24 | 5.01 | 5.01 | 13.49 | 3.24 | Upgrade |
Earnings From Continuing Operations | -997.11 | -1,021 | -1,220 | -1,243 | -1,480 | -1,294 | Upgrade |
Net Income | -997.11 | -1,021 | -1,220 | -1,243 | -1,480 | -1,294 | Upgrade |
Net Income to Common | -997.11 | -1,021 | -1,220 | -1,243 | -1,480 | -1,294 | Upgrade |
Shares Outstanding (Basic) | 64 | 58 | 50 | 44 | 40 | 36 | Upgrade |
Shares Outstanding (Diluted) | 64 | 58 | 50 | 44 | 40 | 36 | Upgrade |
Shares Change (YoY) | 21.74% | 17.48% | 12.64% | 9.20% | 12.26% | 14.01% | Upgrade |
EPS (Basic) | -15.47 | -17.54 | -24.62 | -28.26 | -36.74 | -36.06 | Upgrade |
EPS (Diluted) | -15.47 | -17.54 | -24.62 | -28.26 | -36.74 | -36.06 | Upgrade |
Free Cash Flow | -996.28 | -1,001 | -1,069 | -1,191 | -1,131 | -1,360 | Upgrade |
Free Cash Flow Per Share | -15.46 | -17.19 | -21.58 | -27.08 | -28.09 | -37.91 | Upgrade |
Gross Margin | 56.83% | 55.44% | 58.40% | 55.30% | 59.26% | 51.01% | Upgrade |
Operating Margin | -128.31% | -132.03% | -176.59% | -199.53% | -187.16% | -266.95% | Upgrade |
Profit Margin | -129.68% | -130.73% | -178.77% | -197.03% | -207.58% | -269.06% | Upgrade |
Free Cash Flow Margin | -129.58% | -128.16% | -156.67% | -188.81% | -158.68% | -282.86% | Upgrade |
EBITDA | -985.39 | -1,030 | -1,204 | -1,257 | -1,331 | -1,280 | Upgrade |
EBITDA Margin | -128.16% | -131.88% | -176.41% | -199.29% | -186.75% | -266.18% | Upgrade |
D&A For EBITDA | 1.16 | 1.17 | 1.2 | 1.48 | 2.96 | 3.7 | Upgrade |
EBIT | -986.55 | -1,031 | -1,205 | -1,259 | -1,334 | -1,284 | Upgrade |
EBIT Margin | -128.31% | -132.03% | -176.59% | -199.53% | -187.16% | -266.95% | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.